PT-141 (Bremelanotide)
Also known as: Bremelanotide, Vyleesi, PT-141
Melanocortin receptor agonist (synthetic cyclic peptide analogue of alpha-melanocyte-stimulating hormone [α-MSH])
What it is
PT-141 (bremelanotide) is the active ingredient in Vyleesi, FDA-approved for treating low sexual desire in premenopausal women. It works through brain pathways that regulate sexual arousal, unlike other treatments that act on blood flow. Prescription-only for that indication; also used off-label by men for erectile dysfunction.
The scientific side
Bremelanotide is a synthetic cyclic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) that functions as a non-selective melanocortin receptor (MCR) agonist, with melanocortin type 4 receptor (MC4R) considered the most relevant subtype at therapeutic doses (PMIDs: 33455598, 31429064). MC4R is predominantly expressed in the medial preoptic area (mPOA) of the hypothalamus, an area important for female sexual function. Animal studies suggest bremelanotide may activate presynaptic MC4Rs on neurons in the mPOA, leading to increased release of dopamine, an excitatory neurotransmitter associated with increased sexual desire. Bremelanotide also activates melanocortin receptors 3 and 4 in glioblastoma cell lines, reducing survivin expression and inducing cell death in vitro. MC4R plays a central role in appetite regulation; agonist activity at this receptor promotes satiety. High-resolution structural studies have confirmed bremelanotide's binding mode at full-length MC4R in complex with heterotrimeric Gs protein. Earlier literature noted bremelanotide was also studied via intranasal route and proposed to act in the CNS to promote erections in preclinical models, and to stimulate behaviors facilitating sexual activity in both male and female models (PMIDs: 18552829, 17983889).
Class: Melanocortin receptor agonist (synthetic cyclic peptide analogue of alpha-melanocyte-stimulating hormone [α-MSH])
At a glance
| What it is | Bremelanotide, a synthetic peptide related to alpha-MSH that activates melanocortin receptors in the brain and skin. |
|---|---|
| Approved for | Low sexual desire that causes distress (hypoactive sexual desire disorder, HSDD) in premenopausal women. Sold as Vyleesi. |
| Route | 1.75 mg injected under the skin of the abdomen or thigh with an autoinjector. |
| Dosing cadence | On demand: at least 45 minutes before sexual activity, no more than once in 24 hours and no more than 8 times a month. Not taken on a schedule or cycle. |
| Evidence strength | FDA approved, based on two 24-week phase 3 trials in 1,267 women and a 52-week extension. |
| Key risks | A temporary rise in blood pressure after each dose, nausea in 40% of users, and skin darkening with frequent use. |
What is PT-141?
PT-141 is the research name for bremelanotide, a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). Since 2019 it has been sold in the US as Vyleesi, a prefilled autoinjector, by prescription.
It is related to Melanotan II, but it is approved and dosed very differently. Outside the label, PT-141 is also sold as a research peptide and used by men for sexual function.
How does it work?
Bremelanotide activates several melanocortin receptors, in this order of potency: MC1R, MC4R, MC3R, MC5R and MC2R. The label says that "at therapeutic dose levels, binding to MC1R and MC4R is most relevant." MC4R is found in many brain areas; MC1R sits on pigment cells, which is why repeated use can darken skin.
The label is candid that "the mechanism by which VYLEESI improves HSDD in women is unknown." It works on desire in the brain, not on blood flow like erectile dysfunction drugs.
Pharmacokinetics
| Half-life | About 2.7 hours (label) |
|---|---|
| Metabolism | Broken down by hydrolysis of its peptide bonds (label) |
| Clearance | About 65% of a radiolabeled dose recovered in urine and 23% in feces (label) |
| Route | Subcutaneous injection; peak level about 1 hour after the dose |
Sources: [2]
Is it FDA-approved?
Yes. The FDA approved bremelanotide as Vyleesi on June 21, 2019. The label was last updated in October 2026.
- Brand name: Vyleesi (approved 2019)
- FDA prescribing information
- WADA: Not listed on the 2026 WADA Prohibited List
What is PT-141 prescribed for?
Vyleesi is approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder: low sexual desire that causes marked distress or relationship difficulty and is not due to another medical or psychiatric condition, relationship problems, or a medication.
In the two phase 3 trials, women on bremelanotide had statistically significant increases in desire and reductions in distress compared with placebo. The label says to stop after 8 weeks if there is no improvement, and that it is "not indicated to enhance sexual performance."
FDA-approved use: Hypoactive sexual desire disorder (HSDD) in premenopausal women
Also studied for
- Erectile response in men (intranasal, early 2000s; not approved)
Off-label use: Men use PT-141 for sexual function, but Vyleesi is "not indicated for the treatment of HSDD in postmenopausal women or in men." Early studies in men used a nasal spray at much higher doses.
Who should not use it
- Uncontrolled hypertension
- Known cardiovascular disease
- Not recommended for people at high risk for cardiovascular disease
Dosing and safety monitoring
Blood pressure
Each dose raises blood pressure by up to 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose and usually back to baseline within 12 hours; heart rate drops by up to 5 beats per minute. The label asks prescribers to consider cardiovascular risk and "ensure blood pressure is well-controlled" before starting and periodically during treatment. If you take blood pressure medication or have any heart concerns, check your blood pressure before using it.
Dosing limits
1.75 mg at least 45 minutes before anticipated sexual activity. No more than one dose in 24 hours, because doses close together may add up their effect on blood pressure. More than 8 doses a month is not recommended: it raises the chance of skin darkening and the time each month that blood pressure is raised.
What to watch for
- Skin darkening (focal hyperpigmentation): 1% of women taking up to 8 doses a month; 38% after 8 daily doses in a row in a separate study
- Nausea: 40% of women in the phase 3 trials, the most common side effect
- Slower stomach emptying, which can delay or reduce absorption of oral medicines taken at the same time
Avoid combining with
- Oral naltrexone for alcohol or opioid dependence: Vyleesi may significantly lower naltrexone levels, and naltrexone failing can have severe consequences
- Oral drugs that need a threshold level to work (for example antibiotics), because of slower stomach emptying
Side effects
In the phase 3 trials, the most common side effects (more than 4% of women) were nausea, flushing, injection site reactions, headache and vomiting. Nausea led 8% of women to stop treatment; for most it improves by the second dose.
Each dose briefly raises blood pressure and lowers heart rate. Skin darkening (focal hyperpigmentation) on the face, gums or breasts can occur and did not always fade after stopping. In the 52-week extension, no new safety signals appeared.
Common
- Nausea: 40.0% vs 1.3% on placebo
- Flushing: 20.3% vs 0.3%
- Injection site reactions: 13.2% vs 8.4%
- Headache: 11.3% vs 1.9%
- Vomiting: 4.8% vs 0.2%
Serious
- Temporary blood pressure increase after each dose (up to 6/3 mmHg)
- Focal hyperpigmentation that may not fade
- One case of acute hepatitis in which a role for Vyleesi could not be excluded
FDA label, Table 1: adverse reactions in at least 2% of patients in the 24-week phase 3 trials (1,247 women).
Rare events and case reports
Acute hepatitis case
In the open-label extension of one trial, a woman who had taken 10 doses over a year developed acute hepatitis, with liver enzymes over 40 times the upper limit of normal and bilirubin 6 times normal. Her liver tests returned to normal 4 months after stopping. No other cause was found, so the label says Vyleesi's role "could not definitively be excluded"; there was no wider liver signal across the trials. If you develop abdominal pain, yellowing skin or eyes, dark urine or unusual tiredness while using it, stop and ask a clinician for liver tests (ALT, AST).
Sources: [2]
FAQ
How soon before sexual activity should PT-141 be taken?
At least 45 minutes before. The label says the best timing has not been fully worked out, so people adjust based on how long it lasts for them and on side effects like nausea.
Sources: [2]
Can men use PT-141?
Not as an approved use: the label says Vyleesi is not indicated in men. Early studies in men used a nasal spray, and erections increased at doses above 7 mg.
What are the blood pressure risks?
Each dose raises blood pressure up to about 6/3 mmHg for several hours. It is contraindicated with uncontrolled high blood pressure or known heart disease, and you should not take more than one dose in 24 hours.
What does hyperpigmentation mean here?
Darker patches of skin, gums or breasts. It affected 1% of women using up to 8 doses a month but 38% after 8 daily doses in a row, and it did not always fade after stopping.
Sources: [2]
Why is naltrexone a problem?
Vyleesi can sharply lower the level of oral naltrexone, so naltrexone taken for alcohol or opioid dependence might stop working. The label says to avoid the combination.
Sources: [2]
What happened in the hepatitis case?
One woman in the long-term extension developed acute hepatitis after 10 doses over a year and recovered after stopping. No other cause was found, so a link could not be ruled out. Stop and get liver tests if you notice abdominal pain, jaundice or dark urine.
Sources: [2]
How often can PT-141 be used?
No more than once in 24 hours and no more than 8 times a month. Stop after 8 weeks if it has not helped.
Sources: [2]
Can it be used while breastfeeding?
The October 2026 label says bremelanotide passes into breast milk "in clinically insignificant amounts" (about 0.13% of the mother's dose). Use during pregnancy is not recommended.
Is PT-141 banned in sport?
It is not named on the 2026 WADA Prohibited List. Athletes should still check with their anti-doping organization.
Sources: [9]
Citations
- Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci 2003. PMID 12851303
- VYLEESI (bremelanotide injection) prescribing information, NDA 210557, revised October 2026 (S-005). accessdata.fda.gov/drugsatfda_docs/label/2026/210557s005lbl.pdf
- FDA approval letter for Vyleesi (NDA 210557), June 21, 2019. accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf
- FDA supplement approval letter, NDA 210557 S-005 (Section 8 update), October 22, 2026. accessdata.fda.gov/drugsatfda_docs/appletter/2026/210557Orig1s005ltr.pdf
- Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol 2019. PMID 31599840
- White WB, et al. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. J Hypertens 2017. PMID 27977473
- Simon JA, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019. PMID 31599847
- Diamond LE, et al. Double-blind, placebo-controlled evaluation of intranasal PT-141 in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004. PMID 14963471
- World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
Sources
- FDA label (Vyleesi). VYLEESI (bremelanotide injection) prescribing information, NDA 210557, revised October 2026 (S-005). accessdata.fda.gov/drugsatfda_docs/label/2026/210557s005lbl.pdf
- FDA approval letter, 2019. FDA approval letter for Vyleesi (NDA 210557), June 21, 2019. accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf
- FDA approval letter, 2026. FDA supplement approval letter, NDA 210557 S-005 (Section 8 update), October 22, 2026. accessdata.fda.gov/drugsatfda_docs/appletter/2026/210557Orig1s005ltr.pdf
- Kingsberg 2019. Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol 2019. pubmed.ncbi.nlm.nih.gov/31599840
- Simon 2019. Simon JA, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019. pubmed.ncbi.nlm.nih.gov/31599847
- White 2017. White WB, et al. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. J Hypertens 2017. pubmed.ncbi.nlm.nih.gov/27977473
- Molinoff 2003. Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci 2003. pubmed.ncbi.nlm.nih.gov/12851303
- Diamond 2004. Diamond LE, et al. Double-blind, placebo-controlled evaluation of intranasal PT-141 in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004. pubmed.ncbi.nlm.nih.gov/14963471
- WADA. World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
Administration & storage
- Administration
- Subcutaneous injection via autoinjector — self-administered by patients as needed before sexual activity (PMIDs: 315998403523016231429064)Subcutaneous injection — used in Phase 1 obesity trials (PMID: 35170192)Nasal (intranasal) formulation — referenced in earlier pre-approval literature in the context of male ED studies (PMID: 17584134); not the approved routeIntravenous route — mentioned as a broader category of peptide administration context for PT-141/bremelanotide review (PMID: 40069591)
- Storage
- No storage conditions for bremelanotide are described in the reviewed abstracts.
- Cautions
- Nausea was the most common adverse event in clinical trials (40.0% bremelanotide vs. 1.3% placebo in Phase 3 double-blind studies) and the most common reason for discontinuation.,Focal hyperpigmentation was rare when bremelanotide was dosed per label recommendations but occurred in more than one-third of subjects following up to 16 consecutive daily dosings.,Small but statistically significant transient blood pressure increases were observed; bremelanotide should be used with caution in patients at risk of cardiovascular disease, and blood pressure should be well controlled during treatment.,Clinically significant drug-drug interactions exist: bremelanotide lowered plasma concentrations of indomethacin and naltrexone.,Adverse event-induced study discontinuation was substantially higher on bremelanotide vs. placebo in re-analyses of Phase 3 data (OR=11.98; NNH: 6).,Sterile technique is essential for subcutaneous self-injection to prevent contamination.
Legal & regulatory status
FDA-approved (2019) for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women (PMIDs: 31429064, 37365323, 23147017, 33455598, 35147466). Also noted as containing a…
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women Human RCT
- Two identical Phase 3 randomized double-blind placebo-controlled multicenter trials (RECONNECT; n=1,247 safety population, n=1,202 efficacy population) of bremelanotide 1.75 mg subcutaneous as needed for 24 weeks in premenopausal women with HSDD. Statistically significant increases in sexual desire and reductions in di PMID 31599840 Kingsberg SA et al. Obstetrics and gynecology (2019)
- 52-week open-label extension of RECONNECT (n=684 enrolled, n=272 completed). No new safety signals observed; sustained improvements in HSDD symptoms. Most common treatment-emergent adverse events: nausea (40.4%), flushing (20.6%), headache (12.0%). PMID 31599847 Simon JA et al. Obstetrics and gynecology (2019)
- Phase 2b dose-finding RCT; n=327 premenopausal women. Bremelanotide 1.25/1.75 mg pooled vs. placebo: mean change in satisfying sexual events/month +0.7 vs. +0.2 (p=0.0180), FSFI total score +3.6 vs. +1.9 (p=0.0017), FSDS-DAO total score -11.1 vs. -6.8 (p=0.0014). Adverse events: nausea, flushing, headache. PMID 27181790 Clayton AH et al. Women's health (2016)
- Review of bremelanotide safety from clinical development program (phases 1–3; 3,500 subjects, 43 completed studies). Most common AEs (double-blind phase 3): nausea (40.0% vs. 1.3% placebo), flushing (20.3% vs. 1.3%), headache (11.3% vs. 1.9%), injection site reactions (5.4% vs. 0.5%). Focal hyperpigmentation rare with PMID 35147466 Clayton AH et al. Safety Profile of Bremelanotide. Journal of women's health (2022)
- Prespecified and integrated subgroup analyses from RECONNECT (n=1,202). Bremelanotide achieved statistically significant improvements in desire and distress across age, weight, BMI, and baseline bioavailable testosterone subgroups, with few exceptions. Significant improvements also in patients with and without hormonal PMID 35230162 Simon JA et al. Journal of women's health (2022)
- Re-analysis of Phase 3 bremelanotide trial data found 72.72% of protocol-listed outcomes were not reported; adverse event-induced discontinuation substantially higher on bremelanotide (OR=11.98; NNH: 6); participants preferred placebo over bremelanotide (OR=0.30; NNH: 4). Modest benefits on incompletely reported post-h PMID 33678061 Spielmans GI. Journal of sex research (2021)
- Examination of Phase 3 RECONNECT efficacy measures found questionable validity evidence for primary outcomes (FSFI-D, FSDS-DAO item 13). 8 of 11 pre-specified outcomes were previously unpublished; effect sizes ranged from nil to small across all reported outcomes. PMID 36809187 Spielmans GI, Ellefson EM. Journal of sex research (2024)
- RECONNECT exit surveys (n=242) and telephone interviews (n=80) found bremelanotide-treated patients reported increased feelings of sexual desire, physical arousal, and improvement in overall quality of sexual activities compared with placebo recipients. PMID 33538638 Koochaki P et al. Journal of women's health (2021)
- Responder analyses from Phase 2b dose-ranging study. At 1.75 mg, responder rates achieved statistical significance vs. placebo (P≤0.03) across all 7 endpoints in the overall modified intention-to-treat population. PMID 31277966 Althof S et al. Journal of sexual medicine (2019)
- Female sexual dysfunction (desire, arousal, and orgasmic dysfunction) — broader populations Mixed
- Systematic review and meta-analysis of 36 studies. Bremelanotide improved total FSFI and its desire and arousal subscales in women with FSD of desire, arousal, and/or orgasm (without pain). All three treatments (mindfulness-based CBT, flibanserin, bremelanotide) reduced distress. PMID 40543759 Toledo RG et al. Journal of minimally invasive gynecology (2026)
- Narrative review of 30 systematic reviews and meta-analyses. Bremelanotide effective to improve desire, arousal, and orgasm scores. PMID 35147017 da Silva Lara LA et al. Minerva obstetrics and gynecology (2022)
- Meta-analysis of 8 RCTs using FSFI as outcome. Women receiving placebo improved 3.62 on FSFI; treatment arm (including bremelanotide) increased 5.35. Approximately 67.7% of treatment effect accounted for by placebo, suggesting current FSD treatments are minimally superior to placebo overall. PMID 29995725 Weinberger JM et al. Obstetrics and gynecology (2018)
- Erectile dysfunction (ED) in men — CNS/melanocortinergic mechanism Animal studies only
- Preclinical review: bremelanotide appears to act in the CNS to promote erections in preclinical models and may stimulate behaviors facilitating sexual activity beyond erectogenic effects. PMID 18552829 Shadiack AM et al. International journal of impotence research (2008)
- Review noting bremelanotide (a melanocortin agonist) has been tested in men with ED and may prove to be one of the first centrally acting agents with clinical utility in male sexual dysfunction. PMID 18552830 Hellstrom WJG. International journal of impotence research (2008)
- Review describing Phase II clinical trial data supporting melanocortin-based therapy (bremelanotide, then nasally administered) for erectile dysfunction. Noted as well tolerated and not associated with hypotension observed with PDE5 inhibitors. PMID 17584134 Shadiack AM, Sharma SD et al. Current topics in medicinal chemistry (2007)
- Narrative review: PT-141 shows efficacy for ED through central nervous system activation and nitric oxide regulation; large-scale clinical trials needed to establish safety profiles, optimal dosing, and synergistic effects. PMID 40069591 Ila V et al. Expert opinion on pharmacotherapy (2025)
- Body weight reduction / caloric intake reduction in obese women Human RCT
- Two Phase 1 randomized double-blind placebo-controlled trials in premenopausal obese women (BMI >30 kg/m²). Study A: bremelanotide (subcutaneous, three times daily for 15 days) produced significantly greater weight reduction vs. placebo (LS mean difference -1.3 kg; p<0.0001) and reduced caloric intake ~400 kcal/day. St PMID 35170192 Spana C et al. Diabetes, obesity & metabolism (2022)
- Glioblastoma — cell death induction and growth inhibition (in vitro) In vitro only
- Bremelanotide reduced survivin expression and induced cell death in human glioblastoma cell lines at concentrations not toxic to normal human cells, via melanocortin receptors 3 and 4. Also promoted cell death induced by temozolomide and osimertinib in combination. PMID 39197897 Suzuki S et al. Anticancer research (2024)
Safety signals
- Nausea: most common adverse event (40.0% bremelanotide vs. 1.3% placebo in Phase 3 double-blind integrated studies); most common reason for discontinuation PMID 35147466
- Flushing: 20.3% bremelanotide vs. 1.3% placebo in Phase 3 double-blind integrated studies PMID 35147466
- Headache: 11.3% bremelanotide vs. 1.9% placebo in Phase 3 double-blind integrated studies PMID 35147466
- Injection site reactions: 5.4% bremelanotide vs. 0.5% placebo in Phase 3 double-blind integrated studies PMID 35147466
- Focal hyperpigmentation: rare at label-recommended dosing, but occurred in >1/3 of subjects with up to 16 consecutive daily dosings PMID 35147466
- Small, transient but statistically significant blood pressure increases observed on ambulatory blood pressure monitoring; caution advised in patients at cardiovascular risk PMID 35147466
- Adverse event-induced study discontinuation substantially higher on bremelanotide vs. placebo: OR=11.98 (95% CI 3.74–38.37); NNH: 6 PMID 33678061
- Drug-drug interactions: bremelanotide lowered plasma concentrations of indomethacin and naltrexone (most other drug-drug interactions not clinically significant; no clinically significant interaction with ethanol) PMID 35147466
- Nausea was the only severe treatment-emergent adverse event experienced by more than one participant during the 52-week open-label extension; no deaths and few serious AEs across development program PMID 31599847
- Nausea (39.9%), facial flushing (20.4%), and headache (11%) reported in Phase 3 trials independently by Mayer and Lynch review PMID 31893927
Contraindications
- Caution advised in patients at risk of cardiovascular disease; blood pressure should be well controlled during treatment due to observed transient BP increases PMID 35147466
- Caution advised due to limited efficacy, potential adverse effects, and transparency issues in reporting; pharmacotherapy should be used within a multidisciplinary approach PMID 38767282
- Pregnancy and lactation: listed as subject headings in a drug review (Vyleesi for HSDD), indicating special populations of concern; no explicit contraindication text available from the abstract PMID 31381550
Protocol
1 mg subcutaneous injection, 45-60 min before activity, as needed. Cycle: single dose / on-demand use.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Subcutaneous injection | 1.75 mg | 24 weeks (as needed before sexual activity) | human | Research PMID 31599840 |
| Subcutaneous injection | 1.75 mg (open-label extension, same dose) | 52 weeks | human | Research PMID 31599847 |
| Subcutaneous injection (self-administered) | 0.75 mg, 1.25 mg, or 1.75 mg (dose-finding study); 1.25/1.75 mg pooled for primary analysis | 12 weeks (as desired) | human | Research PMID 27181790 |
| Subcutaneous injection | Study A: subcutaneous bremelanotide three times daily (dose not specified per injection in abstract); Study B: 2.5 mg once daily or 2.5 mg/2.0 mg twice daily | Study A: 15 days; Study B: three 4-day treatment periods | human | Research PMID 35170192 |
| Subcutaneous injection | 1.75 mg (MC4R most relevant subtype at therapeutic doses, per abstract) | Not specified beyond citing phase 3 program | human | Research PMID 33455598 |
| Subcutaneous injection | 1.75 mg (phase 2b; doses tested included multiple levels, 1.75 mg used for responder analysis) | Not explicitly stated in abstract | human | Research PMID 31277966 |
| subcutaneous injection | 1 mg | as needed, approximately 45-60 minutes before sexual activity · single dose / on-demand use | men with erectile dysfunction or low libido, biohackers seeking enhanced sexual performance | [Community] |
| subcutaneous injection | 0.5 mg | as needed, approximately 45-60 minutes before sexual activity · single dose / on-demand use | men or women new to PT-141, or those who experienced nausea at higher doses | [Community] |
| subcutaneous injection | 2 mg | as needed, approximately 45-60 minutes before sexual activity · single dose / on-demand use | men who find 1 mg insufficient, experienced users | [Community] |
| subcutaneous injection | 1 mg | as needed, approximately 45-60 minutes before sexual activity · single dose / on-demand use | women with hypoactive sexual desire disorder (HSDD) or low libido | [Community] |
| subcutaneous injection | 0.5 mg | as needed, approximately 45-60 minutes before sexual activity · single dose / on-demand use | women new to PT-141 or sensitive to nausea | [Community] |
| subcutaneous injection | 1.75 mg | as needed, no more than once per 24 hours · single dose / on-demand use | women; clinician-guided or pharma-protocol users referencing FDA-approved Vyleesi dosing | [Community] |
| intranasal | 0.5 mg | as needed, approximately 60-90 minutes before sexual activity · single dose / on-demand use | biohackers preferring needle-free administration, both men and women | [Community] |
| subcutaneous injection | 1 mg | weekly or bi-weekly, not on-demand · 4-8 weeks | men or women using PT-141 as part of a broader hormonal optimization or TRT protocol | [Community] |
Blends containing this peptide
All studies (25)
- PMID 27181790 Human RCT
Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women - PMID 31277966 Human RCT
Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women - PMID 31599840 Human RCT
Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women - PMID 31599847 Human RCT
Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women - PMID 33538638 Human RCT
Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women - PMID 33678061 Human RCT
Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women - PMID 35147466 Human RCT
Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women - PMID 35170192 Human RCT
Body weight reduction / caloric intake reduction in obese women - PMID 35230162 Human RCT
Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women - PMID 36809187 Human RCT
Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women - PMID 29995725 Mixed
Female sexual dysfunction (desire, arousal, and orgasmic dysfunction) — broader populations - PMID 35147017 Mixed
Female sexual dysfunction (desire, arousal, and orgasmic dysfunction) — broader populations - PMID 40543759 Mixed
Female sexual dysfunction (desire, arousal, and orgasmic dysfunction) — broader populations - PMID 17584134 Animal studies only
Erectile dysfunction (ED) in men — CNS/melanocortinergic mechanism - PMID 18552829 Animal studies only
Erectile dysfunction (ED) in men — CNS/melanocortinergic mechanism - PMID 18552830 Animal studies only
Erectile dysfunction (ED) in men — CNS/melanocortinergic mechanism - PMID 31381550
Pregnancy and lactation: listed as subject headings in a drug review (Vyleesi for HSDD), indicating special populations of concern; no explicit contraindication - PMID 31429064
- PMID 31893927
Nausea (39.9%), facial flushing (20.4%), and headache (11%) reported in Phase 3 trials independently by Mayer and Lynch review - PMID 33455598
1.75 mg (MC4R most relevant subtype at therapeutic doses, per abstract) Subcutaneous injection (human) - PMID 34433901
- PMID 38151009
- PMID 38767282
Caution advised due to limited efficacy, potential adverse effects, and transparency issues in reporting; pharmacotherapy should be used within a multidisciplin - PMID 39197897 In vitro only
Glioblastoma — cell death induction and growth inhibition (in vitro) - PMID 40069591 Animal studies only
Erectile dysfunction (ED) in men — CNS/melanocortinergic mechanism
Frequently asked
What is PT-141 (bremelanotide) and what is it approved for?
PT-141, also known as bremelanotide (brand name Vyleesi), is a synthetic cyclic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) and a melanocortin receptor agonist. It was approved by the U.S. FDA in 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women (PMIDs: 31429064, 37365323, 33455598). It is not approved in Europe as of the reviewed literature. Regulatory status outside the USA requires manual verification.
How does PT-141 work?
Bremelanotide acts as a non-selective melanocortin receptor (MCR) agonist; the melanocortin type 4 receptor (MC4R) is considered the most relevant subtype at therapeutic doses. MC4R is predominantly expressed in the medial preoptic area (mPOA) of the hypothalamus. Animal studies suggest bremelanotide activates presynaptic MC4Rs on neurons in the mPOA, leading to increased release of dopamine — an excitatory neurotransmitter associated with sexual desire. High-resolution structural studies have confirmed its binding mode at MC4R. Bremelanotide is described as modulating central excitatory brain pathways involved in sexual response (PMIDs: 31429064, 33455598).
What dose of PT-141 should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: In the FDA-approved protocol and Phase 3 clinical trials, bremelanotide was used at 1.75 mg subcutaneously, administered as needed approximately 45 minutes before sexual activity, no more than once in 24 hours, and no more than 8 doses per month. Discontinuation after 8 weeks without benefit was recommended. A Phase 2b dose-finding trial also studied 0.75 mg and 1.25 mg doses. Dosing decisions should be made with a licensed healthcare provider.
What are the side effects of PT-141?
In Phase 3 clinical trials (n=1,247), the most common adverse events were: nausea (40.0% vs. 1.3% placebo), flushing (20.3% vs. 1.3%), headache (11.3% vs. 1.9%), and injection site reactions (5.4% vs. 0.5%). Nausea was the most common reason for discontinuation. Focal hyperpigmentation was rare at label-recommended dosing but occurred in >1/3 of subjects with up to 16 consecutive daily dosings. Small, transient blood pressure increases were observed. Drug interactions were noted with indomethacin and naltrexone; no clinically significant interaction with ethanol was found (PMIDs: 35147466, 31893927). Please consult a licensed healthcare provider for personalized safety assessment.
Can PT-141 be used for erectile dysfunction in men?
PT-141 (bremelanotide) has been studied in preclinical models and early clinical trials for erectile dysfunction (ED) in men, with proposed action through central melanocortin pathways (PMIDs: 18552829, 18552830, 17584134, 40069591). Phase II data have been reported, but the compound is not FDA-approved for ED based on the reviewed abstracts; the approved indication is HSDD in premenopausal women. A 2025 narrative review noted large-scale clinical trials are needed to establish safety profiles, optimal dosing, and synergistic effects with existing ED treatments for this population. Please speak with a licensed healthcare provider for guidance on ED treatment options.
Is PT-141 more effective than placebo?
Results are mixed across published analyses. Phase 3 RECONNECT trials showed statistically significant improvements in sexual desire and distress vs. placebo. However, a meta-analysis found approximately 67.7% of the treatment effect for female sexual dysfunction is accounted for by placebo, and a re-analysis of Phase 3 data found modest benefits on incompletely reported measures with participants substantially preferring to continue placebo (OR=0.30; NNH: 4) and substantially higher adverse event-induced discontinuation on bremelanotide (OR=11.98; NNH: 6). Critics have also questioned the validity of primary outcome measures. A systematic review meta-analysis (2026) found bremelanotide improved total FSFI and desire and arousal subscales.
Can PT-141 be stacked with other compounds or medications?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: Bremelanotide was studied as monotherapy in Phase 3 HSDD trials. Noted drug-drug interactions include lowered plasma concentrations of indomethacin and naltrexone; most other drug-drug interactions were not clinically significant, and no significant interaction with ethanol was observed. In vitro, bremelanotide was studied in combination with temozolomide and osimertinib in glioblastoma cell lines. Consult a licensed healthcare provider before combining any compounds.
Is PT-141 approved or legal in Europe or Canada?
Based on the reviewed literature, flibanserin and bremelanotide are the only approved medications for HSDD in the USA; none are approved in Europe. Regulatory status in Canada and other jurisdictions is not stated in the reviewed abstracts and requires manual verification with the relevant regulatory authorities.
Where can I buy PT-141?
I don't recommend vendors or sources. Please consult a licensed provider.
Can PT-141 be used during pregnancy or breastfeeding?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. Note that pregnancy and lactation are listed as special population considerations in a drug review of bremelanotide, and the approved indication is specifically for premenopausal women with HSDD. No detailed safety data on pregnancy or lactation are provided in the reviewed abstracts.
Can PT-141 cause high blood pressure?
Yes, small but statistically significant transient blood pressure increases were observed in ambulatory blood pressure monitoring during bremelanotide's clinical development program. The prescribing guidance noted in published literature advises that bremelanotide should be used with caution in patients at risk of cardiovascular disease, and blood pressure should be well controlled during treatment. Please discuss cardiovascular history with your healthcare provider before use.